Hikma Buys Teligent Assets To Expand Into Canada
Deal Worth $46m For Canadian Sterile Injectable Assets Follows Teligent Bankruptcy
Hikma has snapped up the Canadian sterile injectables assets of bankrupt Teligent in a $46m deal that marks Hikma’s first move into Canada.
You may also be interested in...
After a tough 2022 for its generics business, Hikma is predicting big things for the division this year, raising its full-year guidance from 20% growth to nearly 30% as new CEO Riad Mishlawi prepares to take the reins from the start of September. Meanwhile, the firm has also picked up assets from Akorn following its collapse.
Hikma has passed a milestone with its US injectables portfolio after the latest trio of launches.
Quickfire M&A has been unveiled in Canada, with Juno Pharmaceuticals taking control of the former Nichi-Iko affiliate Omega Laboratories.